Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18591178 | 1.00 | HSD17B10 (0.39) | HSD17B10HDAC8SMN1; SMN2EPHX2RORC | |
| SCHEMBL5984320 | 0.91 | HDAC8 (0.38) | HSD17B10HDAC8SMN1; SMN2EPHX2RORC | |
| SCHEMBL18578188 | 0.90 | HSD17B10 (0.38) | HSD17B10HDAC8SMN1; SMN2EPHX2NR1H2 | |
| SCHEMBL18555027 | 0.90 | HSD17B10 (0.38) | HSD17B10HDAC8SMN1; SMN2EPHX2NR1H2 | |
| SCHEMBL16647802 | 0.90 | HSD17B10 (0.38) | HSD17B10HDAC8SMN1; SMN2EPHX2NR1H2 | |
| SCHEMBL18555341 | 0.90 | HSD17B10 (0.38) | HSD17B10HDAC8SMN1; SMN2EPHX2NR1H2 | |
| SCHEMBL26119834 | 0.90 | HSD17B10 (0.38) | HSD17B10HDAC8SMN1; SMN2EPHX2NR1H2 | |
| SCHEMBL18578416 | 0.89 | HSD17B10 (0.37) | HSD17B10HDAC8SMN1; SMN2EPHX2NR1H2 | |
| SCHEMBL21774436 | 0.89 | HSD17B10 (0.37) | HSD17B10HDAC8SMN1; SMN2EPHX2NR1H2 | |
| SCHEMBL18554788 | 0.89 | HSD17B10 (0.37) | HSD17B10HDAC8SMN1; SMN2EPHX2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | HSD17B10 1063/4885HDAC8 2093/4885SMN1; SMN2 3485/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | HSD17B10 1063/4885HDAC8 2093/4885SMN1; SMN2 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.